The cytotoxic effect of plinabulin is significantly enhanced when combined with LY294002 (PI3K agonist) and rapamycin (mTOR agonist), confirming its role in promoting glioblastoma cell death by inhibiting the PAM pathway. Here, PIK3CG is linked to glioblastoma.